会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 3. 发明授权
    • Method of preparing murine monoclonal antibodies against cell-free
products of activated human T-lymphocytes
    • 制备针对活化的人T淋巴细胞的无细胞产物的鼠单克隆抗体的方法
    • US4596774A
    • 1986-06-24
    • US547941
    • 1983-11-02
    • Tse-Wen ChangNancy T. Chang
    • Tse-Wen ChangNancy T. Chang
    • C07K16/18C12P21/08C12P21/00C12N5/00C12N5/02C12R1/91
    • C07K16/18C07K2317/74Y10S530/806
    • A method of preparing simultaneously monoclonal antibodies specific for different cell-free products of activated human T lymphocytes is disclosed. Human T cells are activated in a medium supplemented with mouse serum rather than conventional calf serum. A supernatant prepared from the activated T cells is used to immunize mice. The dominant immunogens in the supernatant are the cell-free products of human T lymphocytes. The yield of hybrid cells which produce products reactive with cell-free products of human T lymphocytes is enhanced by injecting the immunized mice with a supernatant from mitogen-activated murine splenocytes. In addition, a novel radioimmunoadsorbent assay for screening hybrids to detect production of monoclonal antibodies reactive with cell-free products of human T lymphocytes is disclosed.
    • 公开了同时制备对活化的人T淋巴细胞的不同无细胞产物特异的单克隆抗体的方法。 人T细胞在补充有小鼠血清而不是常规小牛血清的培养基中活化。 使用从活化的T细胞制备的上清液来免疫小鼠。 上清液中的主要免疫原是人T淋巴细胞的无细胞产物。 通过从有丝分裂原激活的小鼠脾细胞中注射免疫小鼠来增强产生与人T淋巴细胞无细胞产物反应的产物的杂交细胞的产量。 此外,公开了一种用于筛选杂交体以检测与人T淋巴细胞的无细胞产物反应的单克隆抗体的产生的新型放射免疫吸附测定法。
    • 7. 发明授权
    • Recombinant enterovirus 71 neutralizing antibodies and applications thereof
    • 重组肠病毒71中和抗体及其应用
    • US07482006B2
    • 2009-01-27
    • US11404770
    • 2006-04-17
    • Tse-Wen ChangJim Jinn-Chyuan SheuLee-Hwa LoNien-Yi ChenYoung-Sun Lin
    • Tse-Wen ChangJim Jinn-Chyuan SheuLee-Hwa LoNien-Yi ChenYoung-Sun Lin
    • A61K39/42C12P21/08C12N15/13C07K16/10
    • C07K16/1009A61K2039/505C07K2317/21C07K2317/52C07K2317/622C07K2319/00
    • Provided is an antibody against enterovirus 71 comprising the amino acid sequence shown in SEQ ID NOS: 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, or 26 or functionally active homologues thereof. Also provided are methods for obtaining the antibody comprising (a) selecting a yeast expressing such an antibody from a yeast library, (b) culturing the yeast under conditions that the antibody is expressed, and (c) recovering the antibody from the culture. Also provided is a process for producing the antibody comprising (a) culturing a host cell under conditions that the antibody is expressed, (b) recovering the antibody from the culture, wherein the host cells are transformed or transfected for expressing the antibody against enterovirus 71. Also provided are pharmaceutical compositions comprising an antibody against enterovirus 71 and a pharmaceutically acceptable carrier or diluent, wherein the antibody has an anti-virus agent or detectable label attached thereto.
    • 本发明提供了包含SEQ ID NO:14,15,16,17,18,19,20,21,22,23,24,25或26所示氨基酸序列的肠道病毒71抗体或其功能活性同系物。 还提供了获得抗体的方法,其包括(a)从酵母文库中选择表达这种抗体的酵母,(b)在表达抗体的条件下培养酵母,和(c)从培养物中回收抗体。 还提供了制备抗体的方法,其包括(a)在表达抗体的条件下培养宿主细胞,(b)从培养物中回收抗体,其中宿主细胞被转化或转染用于表达针对肠道病毒的抗体71 还提供了包含针对肠病毒71的抗体和药学上可接受的载体或稀释剂的药物组合物,其中所述抗体具有附着于其上的抗病毒剂或可检测标记。